Abstract-Recently, it was shown that Rho-kinase plays an important role in blood pressure regulation. However, it is not known whether Rho-kinase is involved in atherogenesis. Monocyte chemoattractant protein-1 (MCP-1) is an important chemokine that regulates monocyte recruitment and atherogenesis. Therefore, we examined the role of Rho and Rho-kinase in the angiotensin (Ang) II-induced expression of MCP-1. Ang II dose-and time-dependently enhanced the expression of MCP-1 mRNA and the protein production in vascular smooth muscle cells. CV11974, an Ang II type 1 receptor (AT 1 -R) specific antagonist inhibited the enhancement of MCP-1 expression by Ang II, suggesting that the effect of Ang II is mediated by the AT 1 -R. Botulinum C3 exotoxin, a specific inhibitor of Rho, suppressed Ang II-induced MCP-1 production. Key Words: angiotensin II Ⅲ peptides Ⅲ muscle, smooth, vascular Ⅲ receptors, angiotensin Ⅲ kinase A ngiotensin (Ang) II has been known to regulate blood pressure, fluid homeostasis, and electrolyte balance. 1 Recent studies have shown that Ang II plays an important role in atherogenesis as well. The physiological functions of Ang II are transmitted into target cells through its specific receptor located in the plasma membrane. Although there are 2 isoforms for the Ang II receptor, the Ang II type 1 receptor (AT 1 -R) 2 and the Ang II type 2 receptor (AT 2 -R), 3 most of the cardiovascular effects of Ang II are ascribed to AT 1 -R. Vascular smooth muscle cells (VSMCs) express AT 1 -R, and Ang II induces the production of growth factors and extracellular matrices through this receptor. We have recently reported that Ang II induced interleukin-6 production in VSMCs and have proposed that the Ang II-induced cytokine plays an important role in the progression of atherosclerosis. 4 Invasion of monocytes into the blood vessel wall is one of the early steps in the development of atherosclerosis. Various cytokines, such as monocyte chemoattractant protein-1 (MCP-1), 5 macrophage inflammatory protein-1, 6 and RANTES (regulated on activation, normal T-expressed and -secreted), 7 are known to regulate the movement of monocytes. Among these factors, MCP-1 is one of the most potent chemoattractants for monocytes or macrophages in vitro and in vivo. MCP-1 expression is induced in response to tumor necrosis factor-␣ or ␥-interferon, 8 thrombin, 9 or interleukin-1␤ 10 in VSMCs. Pathological conditions such as hypercholesterolemia and vascular injury also induce expression of the MCP-1 gene in the vascular wall. Recent studies have suggested that MCP-1 is critical for the progression of atherosclerosis. Targeted disruption of the receptor for MCP-1 (CCR2) attenuated the development of atherosclerosis when the mice were crossed with apoE knockout mice that develop severe atherosclerosis. 11 Rho-kinase, identified as a downstream target of Rho A, has been shown to phosphorylate the myosin-binding subunit of myosin light chain phosphatase and enhance smooth muscle contraction. 12,13 Y-27632, a specific inhibitor of Rho-kinase, is reported to reduce blood pressure in hypertensive rats but not in normotensive rats. 14 Recently, a role of Rho A in Ang IIinduced actin organization in cardiac myocytes has been reported. 15 However, the role of Rho and Rho-kinase in Ang II- induced gene expression has not been determined. In the present study, we examined whether Rho and Rho-kinase were involved in Ang II-induced MCP-1 expression in VSMCs.
A ngiotensin (Ang) II has been known to regulate blood pressure, fluid homeostasis, and electrolyte balance. 1 Recent studies have shown that Ang II plays an important role in atherogenesis as well. The physiological functions of Ang II are transmitted into target cells through its specific receptor located in the plasma membrane. Although there are 2 isoforms for the Ang II receptor, the Ang II type 1 receptor (AT 1 -R) 2 and the Ang II type 2 receptor (AT 2 -R), 3 most of the cardiovascular effects of Ang II are ascribed to AT 1 -R. Vascular smooth muscle cells (VSMCs) express AT 1 -R, and Ang II induces the production of growth factors and extracellular matrices through this receptor. We have recently reported that Ang II induced interleukin-6 production in VSMCs and have proposed that the Ang II-induced cytokine plays an important role in the progression of atherosclerosis. 4 Invasion of monocytes into the blood vessel wall is one of the early steps in the development of atherosclerosis. Various cytokines, such as monocyte chemoattractant protein-1 (MCP-1), 5 macrophage inflammatory protein-1, 6 and RANTES (regulated on activation, normal T-expressed and -secreted), 7 are known to regulate the movement of monocytes. Among these factors, MCP-1 is one of the most potent chemoattractants for monocytes or macrophages in vitro and in vivo. MCP-1 expression is induced in response to tumor necrosis factor-␣ or ␥-interferon, 8 thrombin, 9 or interleukin-1␤ 10 in VSMCs. Pathological conditions such as hypercholesterolemia and vascular injury also induce expression of the MCP-1 gene in the vascular wall. Recent studies have suggested that MCP-1 is critical for the progression of atherosclerosis. Targeted disruption of the receptor for MCP-1 (CCR2) attenuated the development of atherosclerosis when the mice were crossed with apoE knockout mice that develop severe atherosclerosis. 11 Rho-kinase, identified as a downstream target of Rho A, has been shown to phosphorylate the myosin-binding subunit of myosin light chain phosphatase and enhance smooth muscle contraction. 12,13 Y-27632, a specific inhibitor of Rho-kinase, is reported to reduce blood pressure in hypertensive rats but not in normotensive rats. 14 Recently, a role of Rho A in Ang IIinduced actin organization in cardiac myocytes has been reported. 15 However, the role of Rho and Rho-kinase in Ang II-induced gene expression has not been determined. In the present study, we examined whether Rho and Rho-kinase were involved in Ang II-induced MCP-1 expression in VSMCs.
Methods

Reagents
Dulbecco's modified Eagle's medium (DMEM) and FBS were purchased from GIBCO-BRL. Ang II was purchased from the Peptide Institute. BSA was purchased from Sigma Chemical Co.
[␣-32 P]dCTP was obtained from DuPont-NEN. CV11974, a specific AT 1 -R antagonist, was obtained from Takeda Chemical Industries, Ltd. PD123319, a specific AT 2 -R antagonist, was obtained from Warner-Lambert, Park Davis Co. Adenovirus vector expressing the dominant negative mutant of Rho-kinase (AdDNRhoK) has been described previously. 16 Botulinum C3 exotoxin, a specific inhibitor of Rho, was purchased from Calbiochem.Y-27632, a specific inhibitor of Rho-kinase, was obtained from Yoshitomi Chemical Industries, Ltd. Antibodies against the phosphorylated form of extracellular signal-regulated protein kinase (ERK) and ERK were obtained from New England Biolabs. Unless indicated otherwise, other chemical reagents were purchased from Wako Pure Chemicals.
Cell Culture
VSMCs were isolated from the thoracic aortas of Sprague-Dawley rats and maintained as described previously. 4 Passages 5 through 12 were used for the experiments. Cells were grown to confluence in DMEM with 10% FBS, growth-arrested in DMEM with 0.1% BSA for 2 days, and then used for the experiments.
Infection of AdDNRhoK
Confluent VSMCs were washed with PBS twice and incubated with AdDNRhoK at a multiplicity of infection (MOI) of 1 to 30 in PBS for 2 hours at room temperature. Cells were washed 3 times with PBS and incubated in DMEM with 0.1% BSA for 48 hours. Then the cells were stimulated with Ang II.
Northern Blot Analysis
Total RNA was prepared by an acid guanidinium-phenol-chloroform extraction method. 17 Northern blot analyses of MCP-1 mRNA and 18S rRNA were performed as described previously. 4 The radioactivity of the hybridized band of MCP-1 mRNA or rRNA was quantified with a Mac BAS bioimaging analyzer (FUJIFILM).
Quantification of Rat MCP-1 Protein by ELISA
The medium of nonstimulated or Ang II-stimulated VSMCs was collected and centrifuged at 12 000 rpm for 1 minute. The supernatant was stored at Ϫ70°C until assay. A sandwich ELISA for MCP-1 was carried out according to the method reported previously. 18 Briefly, a microtiter plate was coated with mouse anti-rat MCP-1 monoclonal antibody B4 or C4 overnight at 4°C. The plate was washed with 0.05% Tween-20 in Tris-buffered saline (TBS, pH 7.5) and blocked with 0.2% of BSA in PBS. Then, serial dilutions of recombinant rat MCP-1 and test samples were applied to the plate. The incubation was performed at 37°C for 90 minutes, followed by a wash with 0.05% Tween 20 in TBS twice. Then rabbit polyclonal anti-rat MCP-1 antibody was added. After 90 minutes of incubation, the plate was washed twice with TBS. The alkaline phosphataselabeled anti-rabbit IgG(abЈ)2 (Vector Laboratories) and p-nitrophenyl phosphate (Sigma) were added to the plate and incubated at 37°C for 30 minutes. The color was read spectrophotometrically at 405 nm.
Western Blot Analysis
VSMCs were lysed in a sample buffer (50 mmol/L NaCl, 30 mmol/L sodium phosphate, 50 mmol/L NaF, 5 mmol/L EDTA, 10 mmol/L Tris-HCl, pH 7.6, 1% Triton X, 0.5% pepstatin A, 0.2 U/mL aprotinin, 5 mmol/L leupeptin, and 1 mmol/L phenylmethylsulfonyl fluoride) after stimulation. Protein concentration was quantified by a BCA protein assay reagent (Pierce). Twenty micrograms of total protein was electrophoresed on 12% SDS-PAGE and transferred to polyvinylidene difluoride membrane (Immobilon, Millipore Co) electrophoretically (100 V, for 1 hour). Detection of phosphorylated ERK was performed by using enhanced chemiluminescence according to the manufacturer's instructions (Amersham Pharmacia Biotech). It has been shown that phosphorylation of ERK is associated with the activation. 19 Therefore, phosphorylation was taken as a measure of enzymatic activity. The membranes were stripped by incubation in a buffer containing 2% SDS, 100 mmol/L Tris-HCl, pH 7.4, and 100 mmol/L 2-mercaptoethanol at 70°C for 1 hour and reprobed with an antibody against ERK.
Statistical Analysis
Statistical analyses were performed by 1-way ANOVA and a multiple comparison (Fisher exact) test if appropriate. A value of PϽ0.05 was considered to be significant.
Results
Ang II Increased MCP-1 Production
VSMCs were stimulated with Ang II, and MCP-1 protein in the supernatant was measured by sandwich ELISA. As shown in Figure 1A , Ang II dose-dependently increased MCP-1 production at 12 hours of stimulation. CV11974 (10 Ϫ5 mol/L) inhibited the enhancement of MCP-1 protein expression by Ang II (10 Ϫ7 mol/L). However, PD 123,319 (10 Ϫ5 mol/L) did not show a significant effect ( Figure 1B) .
Expression of MCP-1 mRNA by Ang II
Next, we examined the effect of Ang II on MCP-1 mRNA expression. Figure 2A 
Critical Role of Rho and Rho-Kinase in Ang II-Induced MCP-1 Expression
Recently, Ang II-induced Rho A activation was reported. 20 Therefore, we examined whether inhibition of the Rho pathway affected Ang II-induced MCP-1 expression. Botulinum C3 exotoxin, a specific inhibitor of Rho, inhibited Ang II-induced MCP-1 production ( Figure 1C) .
Next, we investigated whether Rho-kinase, a target molecule of Rho A, is involved in Ang II-induced MCP-1 expression. VSMCs were infected with AdDNRhoK at 30 MOI or preincubated with Y-27632 (10 Ϫ5 mol/L), a specific inhibitor of Rhokinase, and then stimulated with Ang II (10 Ϫ7 mol/L) for 12 hours. As shown in Figure 1C , both AdDNRhoK and Y-27632 inhibited the Ang II-induced MCP-1 protein expression; however, the adenovirus vector expressing LacZ (AdLacZ, 30 MOI) that was used as a negative control did not show a significant effect. AdDNRhoK MOI-dependently suppressed the Ang IIinduced MCP-1 mRNA expression (Figure 3 ). Y-27632 also suppressed the Ang II-induced MCP-1 mRNA expression as well.
Y-27632 Did Not Affect Ang II-Induced ERK Activation
Previously, it has been reported that ERK is important for Ang II-induced MCP-1 expression. 21 PD 098,059, a specific inhibitor of ERK kinase, inhibited Ang II-induced MCP-1 expression ( Figure 1C ), confirming the previous report. Therefore, we examined whether the Rho-kinase pathway affects Ang II-induced ERK activation. The Ang II-induced ERK activation was not inhibited by Y-27632 (Figure 4 ).
Discussion
The major findings of the present study are that Ang II induces MCP-1 expression through AT 1 -R in VSMCs and that the Rho-Rho-kinase pathway is critical for Ang IIinduced MCP-1 expression. Recently, it has been reported that Rho A plays an important role in Ang II-induced premyofibril formation by Ang II. 15 However, the pathway linking AT 1 -R and Rho A is not clear. Generally, there are few data involving the mechanism of activation of the Rho A guanine nucleotide exchange factor that activates Rho GTPase by extracellular ligand. 22 Lysophosphatidic acid was reported to activate Rho through G␣13, 23 whereas thrombin activated Rho through G␣12. 24 It has been suggested that G␣ directly binds to the Rho A guanine nucleotide exchange factor. Recently, it has been reported that AT 1 -R is coupled with G␣13 in rat portal vein myocytes. 25 Although it is not clear whether the same G protein is coupled with AT 1 -R in VSMCs, this pathway may link AT 1 -R to Rho A. Another possibility is the epidermal growth factor (EGF) receptor-dependent pathway, because lysophosphatidic acid-induced Rho activation was blocked by a dominant negative version of the EGF receptor. 23 Transactivation of the EGF receptor by Ang II through AT 1 -R is also reported to play a critical role in the signaling of AT 1 -R. 26 Therefore, it may be possible that the EGF receptor-dependent pathway mediates Ang II-induced Rho A activation. However, further investigation is necessary to clarify the mechanisms for Ang II-induced Rho A and Rho-kinase activation.
Recently, a role of ERK in the induction of Ang II-induced MCP-1 expression has been reported. 21 We confirmed the results of the previous report. Stretch-induced ERK activation was blocked by C3 exotoxin or Y-27632, 27 suggesting that the Rho-Rho-kinase pathway regulates stretch-induced ERK activation. However, we showed that Y-27632 did not affect the Ang II-induced ERK activation, and the result is consistent with that of the previous report. 20 These data suggest that Ang II differentially activates the Rho-kinase and ERK pathways. Although the possibility that the ERK pathway activates the Rho-Rho-kinase pathway is not excluded at this point, such an interaction has not been reported.
Rho has been shown to activate serum response factordependent transcription 28 and to activate nuclear factor (NF)-B, a transcription factor. 29 It has been shown that Ang II-induced MCP-1 expression is mediated by NF-B 30 because Ang IIinduced MCP-1 expression was inhibited by pyrrolidone dithiocarbamate (PDTC), which is an antioxidant and an inhibitor of NF-B as well. However, Chen et al 21 failed to observe the effect of PDTC on Ang II-induced MCP-1 expression. We also failed to observe the effect of PDTC on Ang II-induced MCP-1 expression in our VSMCs (data not shown), suggesting that NF-B may not play a dominant role in the induction of MCP-1 by Ang II. The role of serum response factor in MCP-1 gene transcription has not yet been reported. Therefore, further investigation is necessary to determine the Ang II-activated and Rho-kinase-dependent transcription factor that enhances MCP-1 gene transcription.
An increasing body of evidence suggests that monocytes and macrophages play an important role in the progression of atherosclerosis and in plaque instability as well. Disruption of the MCP-1 receptor caused attenuation of atherosclerosis when these mice were crossed with apoE knockout mice. 11 These results suggest the critical role of MCP-1 in atherogenesis. We demonstrated in the present study that Ang II-induced MCP-1 expression in VSMCs via ERK and Rho-kinase pathways. Therefore, it is possible that the beneficial effects of the ACE inhibitor, at least in part, are derived from the inhibition of Ang II-induced cytokine production, as shown in the present study and our previous report. 4 Recently, Uehata et al 14 reported that Y-27632 decreased blood pressure in hypertensive rats and proposed that Rho-kinase may be a target molecule for the treatment of hypertension. Our data suggest that inhibition of the Rho-kinase pathway by Y-27632 or AdDNRhoK may suppress the progression of atherosclerosis by inhibition of MCP-1 expression. Therefore, Rho-kinase may be a novel target for the treatment of high blood pressure and atherosclerosis as well. Ϫ5 mol/L). Phosphorylation of ERK was detected by Western blot analysis using a phospho-specific ERK antibody (top). The membrane was stripped and reprobed with an ERK antibody (bottom). The same results were obtained in other independent experiments (nϭ3), and a representative autoradiograph is shown.
